Under Crossfire

Thromboembolic Risk in Systemic Lupus Erythematosus

Giuseppe A. Ramirez; Maria Efthymiou; David A. Isenberg; Hannah Cohen


Rheumatology. 2019;58(6):940-952. 

In This Article


Patients with SLE have a disproportionate thromboembolic risk throughout their life. Deranged intravascular and systemic immune homeostasis probably synergize with the side effects of drugs and with traditional cardiovascular risk factors to promote long-term vascular injury and acute thrombosis. The spectrum of potentially concurring factors in this setting is extremely broad and only partially understood, as each patient with SLE represents a unique combination of multiple pathogenic events. Therefore individualized patient-tailored treatments, possibly based on the prevalent pathogenic profile, constitute the most promising strategy for the future.